Strong end to VC year as Blend, Naurex and Allakos raise $86m

Venture capital financings for biopharmaceutical companies could end 2012 with a strong showing at the pace that new and early-stage firms are announcing new funding rounds, including at least three deals above $10 million kicking off the last full work week before Christmas and New Year's celebrations.